Group items tagged

Prostate cancer is the most common cancer among men in the United Kingdom. However, Macmillan revealed that prostate cancer diagnoses were down 29 per cent between 2019 and 2020, meaning men weren't seeing their GPs to begin to get diagnosed. Therefore, it is of utmost importance to spot any symptoms and get checked, as an early diagnosis can help not only increase survival rates, but also offer a more varied choice of treatment options. As community pharmacy teams play a fundamental role in educating men who may be concerned about their health it vital to maximise trusted relationship with patients, and it is crucial that pharmacists have access to the correct resources to direct men to seek prostate cancer guidance. Prostate cancer often affects men who are over the age of 50. Those who are at a higher risk of prostate cancer also include those of African-Caribbean family descent, if there has been a family history of the cancer, and poor weight and diet. However, studies have found that community pharmacists play an important role in delivering programmes to improve levels of physical activity and diet of men with prostate cancer.

The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year. Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK. The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024. For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK. The Department of Health and Social Care (DHSC) believes that thousands of men's lives could be saved each year if prostate cancer is detected early with effective screening methods.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Prostate cancer is the most common cancer among men in the United Kingdom, affecting nearly 50,000 men yearly. Combined with the challenges faced across healthcare during COVID-19, new figures show that prostate cancer accounts for a third of cancers not treated due to the pandemic, with 14,000 'missing patients' believed to have not undergone treatment since April 2020. It is more urgent than ever that men are encouraged to get checked, as any set-backs in diagnosis can reduce the pathways available, in turn affecting health outcomes. Community pharmacy teams play a crucial role in signposting the help available for men who may be concerned about their health. Therefore, it is vital that pharmacy teams have access to the information they need to correctly direct men to seek prostate cancer guidance. By maximising the trusted relationship between patients and their pharmacists, more can be done to identify the warning signs, helping men to get an earlier diagnosis.

The National Institute for Health and Care Excellence (NICE) has rejected the use of olaparib on the NHS for treatment of adults with hormone-relapsed prostate cancer with BRCA1 or BRCA2 mutations which has spread to other parts of the body. In a draft guidance issued today (January 5) NICE said evidence around the drug made by AstraZeneca was uncertain and approving it would not be a good use of NHS funds. Current treatment for metastatic prostate cancer that no longer responds to hormone therapy is chemotherapy with docetaxel, cabazitaxel, or radium 223 dichloride - a treatment option for people with symptomatic bone metastases who have already had docetaxel or cannot have it. NICE said: "Clinical trial evidence showed that people taking olaparib have more time before their disease gets worse, and live longer overall, than people having retreatment with abiraterone or enzalutamide. However, retreatment with abiraterone or enzalutamide is not considered effective and is not standard care in the NHS.

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

There are a lot of different symptoms of prostate problems. Some of them simply mean you have an enlarged prostate...

The King's condition is "benign" and he will be treated in the hospital next week for a "corrective procedure", Buckingham Palace said a statement released on Wednesday. "In common with thousands of men each year, the King has sought treatment for an enlarged prostate," the Palace said. Because of the upcoming surgery, Charles had to postpone all meetings and events planned for this week. The Palace informed that the King's public engagements will be "postponed for a short period of recuperation." Charles, 75, wanted to share the details of his diagnosis to encourage more men who may be experiencing symptoms to get their conditions checked.

What initially began as two close friends taking a leisurely walk to escape their everyday routine has evolved into a meaningful endeavour to support the fight against cancer. Jamie Sparrow, Senior Vice President - Commercial, EMENA at Accord Healthcare, and Jamie Durbidge, Owner & Managing Director of Perennial Pharma, will be undertaking a 5-day walking challenge to support The Luke Hart Foundation in raising funds for Cancer Research UK. The two Jamies have been friends for more than 15 years and worked together at Mylan, now Viatris, where Jamie S served as Managing Director, while Jamie D held the position of Sales Director for some years. During the COVID pandemic when everybody was stuck at home, the two friends, both early risers, used to spend hours in the mornings walking and talking over the phone, about anything and everything - work, life, family, the Pharmaceutical Industry, politics, sport, and about challenges that people were having during the lockdown. After continuing this routine for several months, they eventually planned to transform their daily ritual into a "walking and talking" trip to reconnect, catch up on things, and enjoy some time together and with friends who wanted to join them.

Audio link How to know symptoms of Prostate Cancer? What are its main signs and symptoms?